We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 3, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include United Technologies , Medtronic (MDT - Free Report) , Gilead (GILD - Free Report) , Hewlett Packard (HPE - Free Report) and Yum! Brands (YUM - Free Report) .
Top Stock Reports for United Technologies, Medtronic and Gilead
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including United Technologies, Medtronic and Gilead. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
United Technologies’ shares have gained +6.9% in the last six months, outperforming the Zacks Diversified Operations industry, which has lost -12.8% over the same period. United Technologies serves various end-markets, which allows it to remain profitable even during tough economic times. The company has offered a bullish guidance for 2018 on healthy demand trends and is likely to deliver sustainable earnings growth in future with Rockwell merger.
United Technologies remains focused on four key priorities: flawless execution, innovation, structural cost reduction and disciplined capital allocation to fuel its growth engine. However, macroeconomic conditions and fluctuations in foreign currency exchange rates affect the company’s bottom-line growth. A disruption in deliveries from suppliers, capacity constraints, production disruptions, price changes, or decreased availability of raw materials or commodities is likely to have an adverse effect on its ability to meet delivery schedules, thereby increasing its operating costs.
Shares of Medtronic have underperformed the Zacks Medical Products industry in the last three months, losing -4.4% vs. a -0.4% decline. However, Medtronic exited the fiscal third quarter on a solid note. All the major business groups contributed to solid top-line growth at CER, highlighting sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets.
Also, gradually stabilizing CRHF market buoys optimism. The Zacks analyst is encouraged by the company’s healthy global acceptance of its advanced therapies. The receipt of FDA approval for the Riptide Aspiration System under the Neurovascular unit within the RTG business buoys optimism.
The company is also focusing on geographical diversification of its businesses. However, escalating costs and expenses continue to weigh on the bottom line. The company’s reiteration of 2018 guidance despite the projection of favorable foreign currency translation dampens investors’ confidence.
Gilead’s shares have outperformed the Zacks Biotech industry in the last twelve months, increasing +12.3% vs. a decline of -5.1%. Gilead’s HIV franchise continues to gain traction, courtesy of the rapid adoption of TAF-based regimens in the United States and EU. The TAF-based regimens now represent 62% of total HIV prescription volume following the launch of Genvoya, Odefsey and Descovy in 2016.
The Zacks analyst thinks the approval of Gilead’s latest triple HIV therapy, Biktarvy, will likely provide an impetus to the stock as Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy. However, the HCV franchise is under tremendous pressure due to lower patient starts and increasing competition. Both pricing and market share are expected to stabilize by mid-2018 while patient starts are expected to decline further. The company’s guidance for 2018 also lacks luster.
Other noteworthy reports we are featuring today include Hewlett Packard and Yum! Brands.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands
For Immediate Release
Chicago, IL – April 3, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include United Technologies , Medtronic (MDT - Free Report) , Gilead (GILD - Free Report) , Hewlett Packard (HPE - Free Report) and Yum! Brands (YUM - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for United Technologies, Medtronic and Gilead
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including United Technologies, Medtronic and Gilead. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
United Technologies’ shares have gained +6.9% in the last six months, outperforming the Zacks Diversified Operations industry, which has lost -12.8% over the same period. United Technologies serves various end-markets, which allows it to remain profitable even during tough economic times. The company has offered a bullish guidance for 2018 on healthy demand trends and is likely to deliver sustainable earnings growth in future with Rockwell merger.
United Technologies remains focused on four key priorities: flawless execution, innovation, structural cost reduction and disciplined capital allocation to fuel its growth engine. However, macroeconomic conditions and fluctuations in foreign currency exchange rates affect the company’s bottom-line growth. A disruption in deliveries from suppliers, capacity constraints, production disruptions, price changes, or decreased availability of raw materials or commodities is likely to have an adverse effect on its ability to meet delivery schedules, thereby increasing its operating costs.
(You can read the full research report on United Technologies here >>>).
Shares of Medtronic have underperformed the Zacks Medical Products industry in the last three months, losing -4.4% vs. a -0.4% decline. However, Medtronic exited the fiscal third quarter on a solid note. All the major business groups contributed to solid top-line growth at CER, highlighting sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets.
Also, gradually stabilizing CRHF market buoys optimism. The Zacks analyst is encouraged by the company’s healthy global acceptance of its advanced therapies. The receipt of FDA approval for the Riptide Aspiration System under the Neurovascular unit within the RTG business buoys optimism.
The company is also focusing on geographical diversification of its businesses. However, escalating costs and expenses continue to weigh on the bottom line. The company’s reiteration of 2018 guidance despite the projection of favorable foreign currency translation dampens investors’ confidence.
(You can read the full research report on Medtronic here >>>).
Gilead’s shares have outperformed the Zacks Biotech industry in the last twelve months, increasing +12.3% vs. a decline of -5.1%. Gilead’s HIV franchise continues to gain traction, courtesy of the rapid adoption of TAF-based regimens in the United States and EU. The TAF-based regimens now represent 62% of total HIV prescription volume following the launch of Genvoya, Odefsey and Descovy in 2016.
The Zacks analyst thinks the approval of Gilead’s latest triple HIV therapy, Biktarvy, will likely provide an impetus to the stock as Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy. However, the HCV franchise is under tremendous pressure due to lower patient starts and increasing competition. Both pricing and market share are expected to stabilize by mid-2018 while patient starts are expected to decline further. The company’s guidance for 2018 also lacks luster.
(You can read the full research report on Gilead here >>>).
Other noteworthy reports we are featuring today include Hewlett Packard and Yum! Brands.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.